Similar articles

• The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).

  Basile JN. Basile JN. J Diabetes Complications. 2013 May-Jun;27(3):280-6. doi: 10.1016/j.jdiacomp.2012.12.004. Epub 2013 Feb 1. J Diabetes Complications. 2013. PMID: 23375850 Review.
• Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.

  Raskin P. Raskin P. Diabetes Metab Res Rev. 2013 Jul;29(5):347-56. doi: 10.1002/dmrr.2403. Diabetes Metab Res Rev. 2013. PMID: 23463735 Review.
• Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.

  Washburn WN. Washburn WN. J Med Chem. 2009 Apr 9;52(7):1785-94. doi: 10.1021/jm8013019. J Med Chem. 2009. PMID: 19243175 Review. No abstract available.
• Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.

  Washburn WN. Washburn WN. Expert Opin Ther Pat. 2009 Nov;19(11):1485-99. doi: 10.1517/13543770903337828. Expert Opin Ther Pat. 2009. PMID: 19852718 Review.
• SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.

  Jabbour SA. Jabbour SA. Postgrad Med. 2014 Jan;126(1):111-7. doi: 10.3810/pgm.2014.01.2731. Postgrad Med. 2014. PMID: 24393758 Review.